Patient-reported outcomes in patients with cystic fibrosis with a G551D mutation on ivacaftor treatment: results from a cross-sectional study

Table 3 EQ-5D-5L and WPAI results

	G551D/IVA patient group	F508del/SOC patient group	P value
EQ-5D-5L
Index score (0–1), n; LS mean (SE)	72; 0.90 (0.02)	137; 0.81 (0.02)	< 0.01
VAS score (0–100), n; LS mean (SE)	72; 75.7 (1.8)	135; 70.0 (1.4)	0.0136
WPAI
School, n^a	41	53
Productivity loss, n; LS mean (SE)^b	27; 24.62 (6.69)	32; 34.57 (6.73)	0.3242
Daily activities, n	70	135
Activity impairment, LS mean (SE)^c	21.63 (2.95)	28.30 (2.19)	0.08

CF Cystic fibrosis, EQ-5D-5L EuroQol 5-dimensions 5-level questionnaire, IVA Ivacaftor, LS Least squares, SE Standard error, SOC Standard of care, VAS Visual analog scale, WPAI Work Productivity Activity and Impairment Questionnaire
^aA total of 29 students were excluded because they were not in school over the past 2 weeks for reasons other than CF or had missing data
^bProductivity loss: combination of absenteeism and presenteeism representing the percentage of overall impairment due to CF
^cActivity impairment: percentage impact of CF on daily activities

ISSN: 1471-2466